Antihyperlipidemic Potential of Balarishta Prepared by Traditional and Modern Methods in High Fat Diet Induced Hyperlipidemic Rats

The objective of the present study was to evaluate the lipid peroxidation activity and related antihyperlipidemic activity of Balarishta-T and Balarishta-M prepared by traditional and modern methods and its marketed formulation in high fat diet induced hyperlipidemic rats. The antioxidant activity of Balarishta-T and Balarishta-M was increased in concentration dependent manner. Balarishta-T and Balarishta-M inhibited the ferrous sulphate induced lipid peroxidation in a dose dependent manner and showed inhibitory concentration (IC50) value 196.61 μg/ml and 201.72 μg/ml respectively. Oral administration of Balarishta-T and Balarishta-M for nine weeks at the dose of 2 ml/kg significantly reduced serum cholesterol, serum LDL and serum triglycerides while showed significant rise in serum HDL as compared to high fat diet fed control group. Marketed Balarishta also showed significant decrease in serum cholesterol, serum LDL, serum triglycerides and showed significant rise in serum HDL. Atorvastatin (1.2 mg/kg, p.o.) was used as standard antihyperlipidemic drug. Both types of Balarishta as Balarishta-T and Balarishta-M showed significant reduction in atherogenic index as compared to high fat diet fed control group which strongly supports antiatherosclerotic property of Balarishta.